New Delhi, August 19 (HS): Academic software and research publishing solutions provider Icodex Publishing Solutions left investors disappointed on its stock market debut today. Despite a decent IPO subscription, the shares opened well below issue price and quickly tumbled into the lower circuit on the BSE SME platform.
The company had priced its IPO shares at ₹102 apiece, but listing day was grim. Icodex made its debut at ₹81.60, a sharp 20% discount to the issue price. Heavy selling pressure dragged the stock further down to the lower circuit at ₹77.55, locking investors into a first-day loss of nearly 24%.
Icodex’s IPO, valued at ₹42.03 crore, was open for subscription from August 11 to 13. The offer received an average subscription of 3.95 times overall. Demand was significantly higher in the Qualified Institutional Buyers (QIB) segment, which was oversubscribed 33.08 times. Retail investors subscribed 4.67 times, whereas the Non-Institutional Investors (NII) segment managed 1.58 times.
The IPO issue consisted of fresh equity shares worth ₹34.64 crore and an Offer for Sale (OFS) of 7,24,800 shares with a face value of ₹10 each. According to the company’s prospectus, the raised funds will be utilized for purchasing new office space, meeting working capital requirements, and other general corporate purposes.
On the financial front, Icodex has shown strong revenue and profit growth in recent years, as per its disclosed numbers. The company’s net profit rose from ₹1.81 crore in FY 2022-23 to ₹4.40 crore in FY 2023-24, jumping further to ₹8.96 crore in FY 2024-25. Revenue too expanded at a CAGR of over 50%, touching ₹22.08 crore. However, its debt burden has also grown sharply during the same period—from ₹2 lakh in FY 2022-23 to ₹88 lakh in FY 2023-24, and further to a sizeable ₹2.99 crore in FY 2024-25.
Despite the impressive financial growth on paper, the market’s reaction suggests lingering investor concerns—particularly about valuation and rising leverage. With its stock already locked at the lower circuit on debut, Icodex now faces an uphill battle to regain investor confidence in the days ahead.
—————
Hindusthan Samachar / Jun Sarkar
